APA (7th ed.) Citation

Yi, Z., Ma, F., Liu, B., Guan, X., Li, L., Li, C., . . . Xu, B. (2019). Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. BMC Cancer, 19(1), 1. https://doi.org/10.1186/s12885-019-5668-3

Chicago Style (17th ed.) Citation

Yi, Zongbi, Fei Ma, Binliang Liu, Xiuwen Guan, Lixi Li, Chunxiao Li, Haili Qian, and Binghe Xu. "Everolimus in Hormone Receptor-positive Metastatic Breast Cancer: PIK3CA Mutation H1047R Was a Potential Efficacy Biomarker in a Retrospective Study." BMC Cancer 19, no. 1 (2019): 1. https://doi.org/10.1186/s12885-019-5668-3.

MLA (9th ed.) Citation

Yi, Zongbi, et al. "Everolimus in Hormone Receptor-positive Metastatic Breast Cancer: PIK3CA Mutation H1047R Was a Potential Efficacy Biomarker in a Retrospective Study." BMC Cancer, vol. 19, no. 1, 2019, p. 1, https://doi.org/10.1186/s12885-019-5668-3.